Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: Current status and future development

Frontiers in Bioscience

Volumn 10, Issue SUPPL. 2, 2005, Pages 2611-2617

  Normanno, Nicola ^a   De Luca, Antonella ^a   Maiello, Monica R ^a   Mancino, Mario ^a   D'Antonio, Antonio ^a   Macaluso, Marcella ^b   Caponigro, Francesco ^a   Giordano, Antonio ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Temple University   (United States)

Author keywords

Breast Cancer; EGFR; Review; Tyrosine Kinase Inhibitors

Indexed keywords

4 (3 CHLORO 4 FLUOROANILINO) 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AEE 788; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; GROWTH FACTOR; LAPATINIB; LIGAND; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (3 MORPHOLINOPROPOXY) 6 QUINAZOLINYL]ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CARCINOMA; CLINICAL TRIAL; CONCENTRATION RESPONSE; ENZYME ACTIVITY; HUMAN; MOLECULAR RECOGNITION; PATHOGENESIS; PATIENT; PHASE 2 CLINICAL TRIAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TUMOR; TUMOR GROWTH;

EID: 21344467261     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1725     Document Type: Article

References (36)

1. M. B. Sporn & A. B. Roberts: Autocrine Secretion - Ten Years Later. Ann Intern Med 117, 408-414 (1992)
2. D. S. Salomon, R. Brandt, F. Ciardiello & N. Normanno: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19, 183-232 (1995)
3. N. Normanno, C. Bianco, A. De Luca, M. R. Maiello & D. S. Salomon: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10, 1-21 (2003)
4. N. Normanno, M. R. Maiello, M. Mancino & A. De Luca: Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. J Chemother 16 (S4), 36-40, (2004)
5. S. Mason & W. J. Gullick: Type 1 growth factor receptors: an overview of recent developments. The Breast 4, 11-18 (1995)
6. M. A. Olayioye, R. M. Neve, H. A. Lane & N. E. Hynes: The ErbB signalling network: receptor dimerisation in development and cancer. EMBO J 19, 3159-3167 (2000)
7. N. C. Luetteke, T. H. Qiu, S. E. Fenton, K. L. Troyer, R. F. Riedel, A. Chang & D. C. Lee: Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126, 2739-2750 (1999)
8. N. Normanno, C. Bianco, A. De Luca & D. S. Salomon: The role of EGF-related peptides in tumor growth. Front Biosci 6, d685-707 (2001)
9. R. Brandt, R. Eisenbrandt, F. Leenders, W. Zschiesche, B. Binas, C. Juergensen & F. Theuring: Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 19, 2129-2137 (2000)
10. E. P. Sandgren, N. C. Luetteke, R. D. Palmiter, R. L. Brinster & D. C. Lee: Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121-1135 (1990)
11. Y. Matsui, S. A. Halter, J. T. Holt, B. L. Hogan & R. J. Coffey: Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61, 1147-1155 (1990)
12. K. Albain, R. Elledge, W. Gradishar, D. F. Hayes, E. Rowinsky, C. Hudis, L. Pusztai, D. Tripathy, S. Modi & S. Rubi: Open-label, phase II, multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 76(S1), S33 (2002)
13. G. von Minckwitz, W. Jonat, M. Beckmann, A. De Bois, U. Kleeberg, H. Kuhnie, E. Kettner, J. Hilfrich, J. Torode & A. Schneeweiss: A multicenter phase II trial to evaluate Gefitinib ('Iressa', ZD1839) (500 mg/day) in patient with metastatic breast cancer after previous chemotherapy treatment. Eur J Cancer Suppl 1, S133 (2003)
14. J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, S. Gonzalez, V. Guillen, S. Sauleda, S. Averbuch & F. Rojo: Phase II and tumor pharmacodynamic study of Gefitinib (ZD1839) in patient with advanced breast cancer. Proc Am Soc Clin Oncol 22, 7 (2003)
15. J. F. R. Robertson, E. Gutteridge, K. L. Cheung, R. Owers, M. Koehler, L. Hamilton, J. Gee & R. I. Nicholson: Gefitinib (ZD1839) is active in acquired Tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Proc Am Soc Clin Oncol 22, 7 (2003)
16. E. Winer, M. Cobleigh, M. Dickler, K. Miller, L. Fehrenbacher, C. Jones & R. Justice: Phase II multicenter study to evaluate the efficacy and safety of Tarceva™ (Erlotinib HCl, OSI-774) in women with previously treated, locally advanced or metastatic breast cancer. Breast Cancer Res Treat 76(S1), S123 (2002)
17. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman & D. A. Haber: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 350, 2129-2139 (2004)
18. J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson & M. Meyerson: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1458-1461 (2004)
19. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris & H. Varmus, H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U A 101, 13306-13311 (2004)
20. N. Normanno, M. Campiglio, A. De Luca, G. Somenzi, M. R. Maiello, F. Ciardiello, L. Gianni, D. S. Salomon & S. Menard: Cooperative inhibitory effect of ZD1839 ('Iressa') in combination with trastuzumab ('Herceptin') on human breast cancer cell growth. Ann Oncol 13, 65-72 (2002)
21. M. Campiglio, A. Locatelli, C. Olgiati, N. Normanno, G. Somenzi, L. Vigano, M. Fumagalli, S. Menard & L. Gianni: Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 198, 259-68 (2004)
22. C. A. Ritter, R. Bianco, T. Dugger, W. King, S. Ritland, F. Bargiacchi, G. Lewis, M. X. Sliwkowski & C. L. Arteaga: HER2-overexpressing human breast cancer cells selected for Herceptin (trastuzumab) resistance in vivo retain HER2 gene amplification and overexpress HER1/EGF receptor ligands. Proc Am Ass Cancer Res, 44, 1117, (2003)
23. K. L. Blackwell, E. H. Kaplan, S. X. Franco, P. K. Marcom, J. E. Maleski, M. J. Sorensen & M. S. Berger: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 23, 196 (2004)
24. Y. Lu, X. Zi, Y. Zhao, D. Mascarenas & M. Pollak: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst 93, 1852-1857 (2001)
25. H. E. Jones, L. Goddard, J. M. Gee, S. Hiscox, M. Rubini, D. Barrow, J. M. Knowlden, S. Williams, A. E. Wakeling & R. I. Nicholson: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11, 793-814 (2004)
26. A. B. Motoyama, N. E. Hynes & H. A. Lane: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62, 3151-3158 (2002)
27. J. M. Knowlden, I. R. Hutcheson, H. E. Jones, T. Madden, J. M. Gee, M. E. Harper, D. Barrow, A. E. Wakeling & R. I. Nicholson: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044 (2003)
28. J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling & R. I. Nicholson: The antiepidermal growth factor receptor agent Gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144, 5105-5117 (2003)
29. M. M. Moasser, A. Basso, S. D. Averbuch & N. Rosen: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61, 7184-7188 (2001)
30. R. Bianco, I. Shin, C. A Ritter, F. M. Yakes, A. Basso, N. Rosen, J. Tsurutani, P. A. Dennis, G. B. Mills & C. L. Arteaga: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 2812-2822 (2003)
31. Q. B. She, D. Solit, A. Basso & M. M. Moasser: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9, 4340-4346 (2003)
32. M. R. Maiello, A. De Luca, S. Guy, M. Campiglio, S. Menard & N. Normanno: Characterization of human breast cancer cell lines with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib (Iressa, ZD19839). Proc Am Ass Cancer Res 44, 1075 (2003)
33. M. Guix, M. C. Kelley, M. L. Reyzer, Z. Joan, Y. Shyr, B. K. McLaren, K. Johnson, W. Lipscomb, T. C. Dugger & C. L. Arteaga: Short course of EGFR tyrosine kinase inhibitor erlotinib (OSI-774, 'Tarceva') reduces tumor cell proliferation and active MAPK in situ in untreated operable breast cancers: a strategy for patient selection into phase II trials with signaling inhibitors. Breast Cancer Res Treat 88(S1), S34 (2004)
34. N. Normanno, M. Campiglio, A. De Luca, G. Somenzi, M. R. Maiello, F. Ciardiello, L. Gianni, D. S. Salomon & S. Menard: Cooperative inhibitory effect of ZD1839 ('Iressa') in combination with trastuzumab ('Herceptin') on human breast cancer cell growth. Annals of Oncology 13, 65-72 (2002)
35. S. L. Moulder, F. M. Yakes, S. K. Muthuswamy, R. Bianco, J. F. Simpson & C. L. Arteaga: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (er6B2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61, 8887-8895 (2001)
36. M. Macaluso, C. Cinti, G. Russo, A. Russo & A. Giordano: pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene 22, 3511-3517 (2003)